Provides for the ancillary expenses of state government
HB 463 is Louisiana’s annual ancillary funds appropriations bill for Fiscal Year 2025-2026. It establishes and reestablishes a series of internal service funds, auxiliary accounts, and enterprise funds used by state agencies and institutions to operate self-supporting or cost-reimbursement services. The bill appropriates money for agency working capital, authorizes the deposit and expenditure of self-generated revenues, interagency transfers, federal funds, statutory dedications, and fees, and sets rules for how year-end balances, equity, and unexpended cash are handled.
The bill also contains statewide administrative provisions governing these funds. It requires expenditures to comply with public bid laws, allows revenue increases to be added to appropriations with approval from the commissioner of administration and the Joint Legislative Committee on the Budget, and sets staffing and internal audit requirements for larger agencies. It further directs the commissioner to adjust performance objectives and, in some cases, transfer functions, positions, assets, and funds to improve efficiency in technology and procurement-related operations. The act becomes effective July 1, 2025.
HB 463 affects state budget administration rather than creating a new programmatic policy area. It appropriates and reauthorizes operating funds for a wide range of state entities, including the Office of Group Benefits, Office of Risk Management, Louisiana Property Assistance Agency, Prison Enterprises, Office of Technology Services, Division of Administrative Law, Office of State Procurement, Office of Aircraft Services, and environmental revolving loan funds. It also includes a specific directive that the Office of Group Benefits add semaglutide medications for weight loss coverage if doing so does not increase self-insurance fund costs in FY 2025-2026. The bill therefore influences how these agencies finance operations, manage cash balances, and deliver services, while leaving the underlying statutory structure of most programs intact.
The bill appears to have been broadly supported and noncontroversial in the legislature. It passed the House 98-0, the Senate 39-0, and later received unanimous House concurrence on Senate amendments, indicating strong bipartisan agreement. The lack of recorded committee transcripts suggests there was little publicly documented debate or opposition during the legislative process.
There is little evidence of major contention in the available record, but the most notable policy-specific provision is the requirement that the Office of Group Benefits cover semaglutide for weight loss if it can do so without additional cost to the self-insurance fund. That kind of coverage mandate could be a point of concern for fiscal managers or benefit administrators because it ties a health benefit expansion to cost neutrality. More generally, the bill’s provisions allowing the commissioner of administration and the Joint Legislative Committee on the Budget to approve revenue and staffing changes, and authorizing transfers of functions and assets for efficiency purposes, reflect administrative discretion that could draw attention from agencies affected by consolidation or reorganization.